0
Moleculin Biotech, Inc. Banner Image

Moleculin Biotech, Inc. has reached its limit for free report views

Work for Moleculin Biotech, Inc.? Upgrade Your Profile and unlock all your annual reports.

Moleculin Biotech, Inc.

  • Ticker MBRX
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Moleculin Biotech, Inc. Logo Image
  • 11-50 Employees
  • Based in Houston, Texas
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors and viruses. The Company's clinical stage drugs are: Annamycin, a Next Generation Anthracycline, designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for theMore treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic cancer and hematologic malignancies, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in preclinical development of additional drug candidates, including other Immune/Transcription Modulators, as well as WP1122 and related antimetabolite compounds capable of Metabolism/Glycosylation Inhibition.
Moleculin Biotech, Inc.

Most Recent Annual Report

Moleculin Biotech, Inc. MOST RECENT 2019 Annual Report and Form 10K

Report Locked. Moleculin Biotech, Inc. has reached its limit for free report views.

Older/Archived Annual Reports